Sign up
Pharma Capital

Sareum announces £700,000 fundraising to support drug development programmes

The company placed 100 mln new ordinary shares of 0.025p each at a price of 0.7p per share
drugs
Sareum is a specialist cancer drug discovery and development company

Sareum Holdings PLC (LON:SAR) has raised £700,000, before expenses, through a share placement to support drug development programmes and supply working capital.

The specialist cancer drug discovery and development company placed 100 million new ordinary shares of 0.025p each at a price of 0.7p per share.

READ: Latest preclinical data for Sareum’s cancer fighting Chk1 inhibitor impresses

Application has been made for the placing shares to be admitted to trading on the London Stock Exchange, which is expected to happen on 22 November.

The company will have a total of 2.7 billion shares in issue after the placing.

View full SAR profile

Sareum Holdings Plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.